Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2016
At a glance
- Drugs Dasatinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 19 Dec 2016 Primary endpoint (Overall survival) has not been met, according to results published in the Annals of Oncology journal.
- 19 Dec 2016 Results of this study, published in the Annals of Oncology journal.
- 12 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History